Digital biomarkers show early clinical validity and provide greater confidence in Movement Disorder clinical trials

YPrime announces a new report unveiling the top challenges that clinical trial executives face when implementing eCOA, and what to look for when evaluating new solutions.

Digital biomarkers provide a pathway to the future where clinical trial sponsors can potentially benefit from reduced trial duration and sample size. Learn more about these benefits from a simulated study.

Explore the five key advantages that underscore the significance of digital measurements in the context of clinical trials